3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other
2
Head & Neck
2
Conditions
Stomatitis
2
Mucositis
2
Mouth Neoplasms
2
Head and Neck Neoplasms
2
Neuroendocrine Tumors
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
4
angiotensin I (1-7)
3
Radiotherapy
3
Radiation
3
Injections
3
Water
2
RRx-001
2
Interleukin 1 Receptor Antagonist Protein
2
Drug Therapy
2
Amifostine
2
tempol
1
peppermint oil
1
pegfilgrastim
1
kang-lai-te
1
hydrated silica gel-based toothpaste
1
golotimod
1
glucarpidase
1
fish oil triglycerides
1
calcium phosphate
1
brilacidin
1
anise oil
1
amlexanox
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Xylitol
1
Vaccinium myrtillus extract
1
Tramadol
1
Therapeutics
1
Surgical Procedures, Operative
1
Sorbic Acid
1
Sodium Bicarbonate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Mucositis
×
RRx-001
×
Clear all
NCT05966194
2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2
Recruiting
216 enrolled
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts